- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BRIDGEBIO ONCOLOGY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.06. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.06. | Oppenheimer initiates BridgeBio Oncology stock rating at Outperform | 1 | Investing.com | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -$526.11 | 2 | Seeking Alpha | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc.: BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress | 328 | GlobeNewswire (Europe) | Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programsAnnounced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818... ► Artikel lesen | |
| 12.05. | BridgeBio Oncology Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 12.05. | BridgeBio Oncology Therapeutics, Inc.: BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 29.04. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.04. | BridgeBio Oncology presents preclinical data on KRAS inhibitor | 10 | Investing.com | ||
| 22.04. | BridgeBio Oncology Therapeutics, Inc.: BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 | 2 | GlobeNewswire (USA) | ||
| 22.04. | BridgeBio Oncology names Pedro Beltran as new CEO | 1 | Investing.com | ||
| 22.04. | BridgeBio Oncology Therapeutics appoints new CEO and COO | 3 | Seeking Alpha | ||
| 22.04. | BridgeBio Oncology Therapeutics, Inc.: BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman | 330 | GlobeNewswire (Europe) | Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development... ► Artikel lesen | |
| 21.04. | BridgeBio Oncology presents preclinical data on BBO-10203 | 1 | Investing.com | ||
| 21.04. | BridgeBio Oncology Therapeutics, Inc.: BBOT Presents Preclinical Data Showing RAS:PI3Ka Breaker BBO-10203 Inhibits PI3Ka/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 | 3 | GlobeNewswire (USA) | ||
| 20.04. | BridgeBio Oncology rises on Fast Track status for pancreatic cancer asset | 3 | Seeking Alpha | ||
| 20.04. | BridgeBio Oncology Therapeutics, Inc.: BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma | 232 | GlobeNewswire (Europe) | BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutant solid tumors Updated Phase 1 clinical data are expected... ► Artikel lesen | |
| 13.04. | BridgeBio Oncology Therapeutics, Inc.: BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 26.03. | BridgeBio Oncology Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | BridgeBio Oncology Therapeutics, Inc.: BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 114,76 | +1,10 % | KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug | ||
| QIAGEN | 34,075 | -2,59 % | QIAGEN NV - Stabilität als strategischer Anker | ||
| APOGEE THERAPEUTICS | 133,52 | +0,46 % | AbbVie-Aktie: Apogee-Übernahme beflügelt | Die AbbVie-Aktie hat den Wegfall des einstigen Blockbusters Humira deutlich besser verkraftet als viele Anleger erwartet hatten. Mit der milliardenschweren Übernahme von Apogee Therapeutics will der... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +4,21 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| IMMUNOVANT | 38,600 | -0,49 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,060 | -2,77 % | What's Going on with Vera Therapeutics Stock on Monday? | ||
| PRAXIS PRECISION MEDICINES | 313,04 | -1,72 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 35,330 | +1,55 % | Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More | ||
| ABSCI | 11,525 | -0,82 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 37,010 | -0,67 % | Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline | ||
| SUMMIT THERAPEUTICS | 15,940 | +3,37 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| DYNE THERAPEUTICS | 22,845 | -0,98 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| ERASCA | 18,860 | +2,11 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,880 | -0,37 % | Leerink raises Moonlake stock price target on HS drug data | ||
| RELAY THERAPEUTICS | 18,910 | +1,39 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen |
Das Unternehmen BRIDGEBIO ONCOLOGY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,70 % bei einem Aktienkurs von 8,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRIDGEBIO ONCOLOGY THERAPEUTICS INC finden Sie auf Wallstreet Online.